Discover which therapies are expected to grab the PD/L-1 Market Share @ PD/L-1 Treatment Market Size ...

We congratulate the six researchers at the Department of Medicine, Huddinge who have been awarded grants from the Swedish ...

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, ...

cryoablation in addition to allogenic NK cell immunotherapy24 could significantly increase the RR and DCR compared with cryoablation alone. Another study found that cryoablation combined with ...

A review discussing the therapeutic potentials of NK cell biology has been published in the journal Frontiers of Medicine.

Artiva Biotherapeutics specializes in advancing a novel NK cell therapy platform targeting autoimmune diseases. The company's approach utilizes unengineered NK cells derived from cord blood ...

Artiva Biotherapeutics specializes in advancing a novel NK cell therapy platform targeting autoimmune diseases. The company's approach utilizes unengineered NK cells derived from cord blood, combined ...

Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and Maintenance Regimens ...

NK cell therapy is gaining momentum as a promising solution to unmet medical needs in cancer treatment, offering safer, targeted options for patients unresponsive to traditional therapies. Increased R ...

Chromosomal Chaos Promotes Therapy Resistance in Leukemia Cells and Opens Up New Treatment Approaches Nov. 25, 2024 — Chromosomal instability plays a crucial role in the progression of cancer ...

The results were so strong in showing the benefit of this therapy ... cell lung cancer is still underway, with results expected within the year. "Our aim is to show that adding high-dose, IV ...